Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)

PHASE3CompletedINTERVENTIONAL
Enrollment

349

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions
Diabetes Mellitus, Type 2Renal Insufficiency
Interventions
DRUG

vildagliptin

50mg qd

DRUG

Placebo

qd

Trial Locations (90)

Unknown

Clinica de Fracturas y Ortopedia, Buenos Aires

Hospital Teodoro Alvarez, Buenos Aires

Instituto de Investigaciones Clinicas de Mar del Plata, Buenos Aires

Instituto Medico Especializado IME, Buenos Aires

Hospital Juan Ramon Vidal, Corrientes

Clinica Reina Fabiola, Córdoba

Hospital Zenon J. Santillan, San Miguel de Tucumán

The Queen Elizabeth Hospital, Woodville

Heidelberg Repatriation Hospital, Heidelberg Heights

SA Endocrine Clinical Research, Keswick

Keogh Medical Research Institute, Nedlands Perth

St Vincent's Hospital (Melb), Victoria

ERS Endocrine Research Society, Vancouver

Health Sciences Centre - Diabetes Research Group, Winnipeg

Co Medica Research Network Inc., Courtice

Ultra Med Inc., Pointe-Claire

Centre de Recherche de Laval, Laval

Private Office (Gottesman), Ontario

Hopital Maisonneuve-Rosemont, Québec

Health Sciences Centre - Diabetes Research Group, Winnipeg

Clínica Vía San Juan, Cartago

Clínica de Endocrinología y Diabetes, San José

Clínica San Agustín, San José

Hospital Clínica Bíblica, San José

Satakunnan Keskussairaala, Pori

Mediwest Research Center, Seinäjoki

Tampereen lääkärikeskus Oy, Koskiklinikka, Tampere

Cabinet du Dr Arnou, Angers

Cabinet du Dr Giraud Philippe, Angers

Hôpital Docteur Duchenne, Boulogne-sur-Mer

Hopital Albert Michallon, Grenoble

Cabinet médical, Laval

Hopital Dupuytren, Limoges

Hopital Edouard Herriot, Lyon

Zentralklinikum Augsburg, Augsburg

Praxis Dr. Maxeiner, Bad Kreuznach

Universitaetsklinik Charitè, Berlin

Praxis Dr. Fischer, Darmstadt

Praxis Dr. Merker, Dormagen

Univ.-Klinikum Erlangen, Erlangen

Kardiol. Gemeinschaftspraxis PD Dr. Winkelmann, Frankfurt

Universitätsklinikum Frankfurt, Frankfurt

Medizinische Hochschule Hannover, Hanover

Friedrich Schiller Universitaet Jena, Jena

CRS Clinical Research Services Gmbh, Kiel

I. Medizinische Univ.-Klinik, Kiel

Praxis Dr. Hennig, Meissen

Praxis Dr. Grimm, München

Univ.-Klinikum München, Campus Innenstadt, München

Praxis Dr. Schoell, Nuremberg

Forschungszentrum Ruhr, KliFoCenter GmbH, Witten

Universitaetsklinik im Luitpold-Krankenhaus, Würzburg

Gujarat Endocrine Centre, Ahmedabad

M V Hospital for Diabetes and Diabetic Research Center, Chennai

Coimbatore Diabetes Foundation, Coimbatore

S.R. Kalla Memorial Gastro & General Hospital, Jaipur

Meenakshi Mission Hospital & Research Centre, Madurai

Diabetes Clinic & Research Centre, Nagpur

Storoklinikken, Oslo

St. Olavs Hospital, Endokrinologisk seksjon, Trondheim

City Clinical Hospital #6, Chelyabinsk

City Clinical Hospital #1, Moscow

City Clinical Hospital No.11, Moscow

MSU of Medicine and Dentistry on the base of CityHospital 23, Moscow

MSUMD on the base of City Clinical Hospital #67, Moscow

City polyclinic # 17, City Diabetic Centre #3, Saint Petersburg

Krestovsky Island Medical Institute, Saint Petersburg

Saint- Petersburg State Mtchnikov's Medical Academy, Saint Petersburg

Saint-Petersburg State Pavlov's Medical University, Saint Petersburg

Site Management Organisation of Clinical Trials Centers, Smolensk

Tyumen State Medicine Academy, Tyumen

Clinica Mediterranea de Neurociencias, Alicante

Hospital de la Ribera, Alzira

Hospital Clinic I Provincial de Barcelona, Barcelona

Centro de Salud Begonte, Begonte

Hospital San Pedro de Alcantara, Cáceres

Hospital Universitario Reina Sofia, Córdoba

Hospital General de Jerez de La Frontera, Jerez de la Frontera

Ciutat Sanitaria I Universitaria de Bellvitge, L'Hospitalet de Llobregat

Complejo Universitario de San Carlos, Madrid

Hospital de Merida, Mérida

Hospital Son Dureta, Palma de Mallorca

Consorci Hospitalari Parc Tauli, Sabadell

Hospital Clinico Universitario Santiago de Compostela, Santiago de Compostela

Eap El Remei - Vic, Vic

ME3PLUS Clinical Trials, Gothenburg

Njurmedicin, Sahlgrenska Univ.sjukhuset, Gothenburg

Metabolmottagningen, Lasarettet, Kristianstad, Kristianstad

VO Endokrinologi/Diabetologi Universitetssjukhuset, Lund

Ladulaas Kliniska Studier, Skene

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00765830 - Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension) | Biotech Hunter | Biotech Hunter